Polyclonal Anti-TNFRSF10A

Price

200.00 USD

Size

100ug/vial

Reactivities

Hum

Format

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

References

1. Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., Ashkenazi, A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7: 1003-1006, 1997. \n2. Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., Dixit, V. M. The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113, 1997.\n

Storage Temp

At -20 degree C for one year. After reconstitution, at 4 degree C for one month. It can also be aliquotted and stored frozen at -20 degree C for a longer time.Avoid repeated freezing and thawing.

Scientific Background

TNFRSF10A (Tumor Necrosis Factor Receptor Subfamily Member 10A), also known as APO2, DR4 or TRAILR1, is a protein that in humans is encoded by the TNFRSF10A gene. The protein encoded by this gene is a member of the TNF-receptor superfamily. By analysis of radiation hybrids, Marsters et al. (1997) mapped the DR4 gene to 8p21. The TRAIL receptor DR5, and 2 decoy receptors for TRAIL, DCR1, and DCR2, are located in the same region, suggesting that these receptors arose from recent gene duplication events. Pan et al. (1997) found that, as with FAS, TNFR1, and DR3, overexpression of DR4 induced apoptosis. However, unlike the other 3 death receptors, DR4 did not use FADD to transmit the death signal, suggesting the use of distinct proximal signaling machinery.